Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A4250 in Pediatric Cholestasis
NCT02630875Phase 2Completed
- Sponsor
- Albireo Pharma
- Start
- Aug 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of odevixibat in cholestatic pruritus, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), biliary atresia, Primary Sclerosing Cholangitis (PSC), sponsored by Albireo Pharma. Started Aug 2015; status: completed.
02
Drugs
odevixibat
03
Conditions
cholestatic pruritusprogressive familial intrahepatic cholestasis (PFIC)Alagille syndrome (ALGS)biliary atresiaPrimary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT02630875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630875.